Allergy Medications: Antihistamines, Steroids, and Decongestants

Allergy medications span three primary pharmacological classes — antihistamines, corticosteroids, and decongestants — each targeting a distinct point in the allergic response cascade. Understanding how these drugs work, how they are classified by the U.S. Food and Drug Administration (FDA), and where their clinical tradeoffs lie is foundational to evaluating treatment options for conditions ranging from allergic rhinitis to anaphylaxis. This page provides a reference-grade breakdown of mechanism, classification, safety framing, and common misconceptions for all three drug classes.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps
• Reference Table or Matrix

Definition and Scope

Allergy medications are pharmacological agents that interrupt, suppress, or reverse the physiological processes triggered by immune hypersensitivity reactions. The FDA regulates these compounds under 21 CFR parts covering over-the-counter (OTC) drug monographs and new drug applications (NDAs), establishing approved active ingredients, dosage limits, and labeling standards for each class.

The three classes covered here address overlapping but mechanistically distinct targets:

• Antihistamines block histamine receptors to prevent or reduce the symptomatic expression of mast cell degranulation.
• Corticosteroids (in the allergy context, primarily intranasal and inhaled formulations) suppress upstream inflammatory gene transcription.
• Decongestants reduce nasal mucosal swelling by vasoconstriction, addressing congestion that antihistamines alone do not reliably resolve.

The broader landscape of allergy management also includes leukotriene receptor antagonists, mast cell stabilizers, biologics (such as anti-IgE monoclonal antibodies), and allergy immunotherapy, which are outside the scope of this page but addressed in the allergy medications overview.

Core Mechanics or Structure

Antihistamines

Histamine exerts its pro-inflammatory effects primarily through H1 receptors located on smooth muscle, vascular endothelium, and sensory neurons. First-generation antihistamines — including diphenhydramine and chlorpheniramine — are lipophilic compounds that cross the blood-brain barrier readily. This property accounts for both their sedating side-effect profile and their documented impairment of psychomotor performance.

Second-generation antihistamines — including cetirizine, loratadine, and fexofenadine — were developed with lower CNS penetrance. Fexofenadine in particular demonstrates limited P-glycoprotein substrate activity, which further restricts CNS access (FDA Drug Approval Package, NDA 20-872). These compounds competitively antagonize H1 receptors and also carry some inverse agonist activity, meaning they can reduce constitutive receptor signaling even in the absence of histamine.

Corticosteroids

Intranasal corticosteroids (INCs) such as fluticasone propionate, budesonide, and mometasone furoate bind to intracellular glucocorticoid receptors (GRs). The GR-ligand complex translocates to the nucleus and modulates transcription of genes encoding inflammatory mediators — including cytokines IL-4, IL-5, and IL-13, which are central to the Th2-dominant immune profile characteristic of allergic disease.

The anti-inflammatory effect of INCs is not immediate; peak efficacy typically requires 1 to 2 weeks of consistent use, a pharmacokinetic reality that has direct implications for patient expectations.

Decongestants

Oral and topical decongestants — primarily pseudoephedrine and oxymetazoline — act as sympathomimetics. Pseudoephedrine stimulates alpha-adrenergic receptors on nasal vasculature, producing vasoconstriction and reducing mucosal edema. Oxymetazoline acts directly as an alpha-2 adrenergic agonist when applied topically. The FDA's Combat Methamphetamine Epidemic Act of 2005 (incorporated into the USA PATRIOT Act reauthorization) placed pseudoephedrine behind pharmacy counters and imposed daily purchase limits of 3.6 grams and monthly limits of 9 grams (DEA Diversion Control Division).

Causal Relationships or Drivers

The allergic response that these medications target begins with sensitization: initial allergen exposure causes antigen-presenting cells to prime naive T cells toward a Th2 phenotype, driving IgE production. On re-exposure, allergen cross-links IgE bound to high-affinity FcεRI receptors on mast cells and basophils. Within seconds to minutes, these cells degranulate, releasing preformed histamine, tryptase, and heparin (the early-phase response), followed hours later by de novo synthesis of leukotrienes, prostaglandins, and cytokines (the late-phase response).

Antihistamines primarily interrupt early-phase symptoms. Corticosteroids suppress both phases by reducing the transcription of multiple inflammatory mediators. Decongestants address a downstream vascular consequence — not the immune mechanism itself — making them symptom-specific rather than disease-modifying.

The regulatory context for allergy governs how these mechanistic claims can be made in drug labeling, with the FDA requiring substantial evidence of efficacy claims tied to specific symptom endpoints.

Classification Boundaries

FDA OTC vs. Prescription Status

The FDA's OTC drug review process has progressively moved antihistamines and selected INCs from prescription to OTC status. As of the FDA's 2022 authorization, fluticasone propionate nasal spray (originally approved as prescription-only under NDA 019839) is available OTC under specific labeling (FDA, Flonase OTC Approval). Triamcinolone acetonide nasal spray similarly received OTC status.

Generation Classification (Antihistamines)

*"Third generation" is a marketing-influenced term with limited regulatory recognition; the FDA does not formally use this generational taxonomy in its classification framework.

Topical vs. Systemic Corticosteroids

Topical formulations (intranasal, inhaled) are classified separately from systemic oral corticosteroids (prednisone, prednisolone) for allergy use. Systemic corticosteroids carry a substantially different risk profile — including hypothalamic-pituitary-adrenal (HPA) axis suppression — and are not considered first-line agents for chronic allergic conditions under NHLBI Asthma Guidelines (EPR-3).

Tradeoffs and Tensions

Antihistamine Sedation vs. Efficacy

First-generation antihistamines demonstrably impair driving performance. A study published in the Annals of Internal Medicine (Betts et al.) established that diphenhydramine impaired driving performance more than a blood alcohol concentration of 0.1% in controlled settings. Despite this, diphenhydramine retains widespread OTC availability and is a primary ingredient in most OTC sleep aids. The FDA's OTC monograph for nighttime sleep aids (21 CFR §338) permits this dual use, creating a tension between the anti-allergy classification context and the sleep-aid context.

Rebound Congestion (Rhinitis Medicamentosa)

Topical oxymetazoline use beyond 3 to 5 consecutive days is clinically associated with rhinitis medicamentosa — rebound nasal congestion caused by down-regulation of adrenergic receptors and compensatory vasodilation. This is a well-documented pharmacological consequence, not an idiosyncratic reaction, and is reflected in FDA-mandated labeling that restricts oxymetazoline use to no more than 3 days.

Intranasal Corticosteroid Systemic Absorption

Although INCs are formulated for minimal systemic absorption, high-dose or prolonged use carries a measurable, dose-dependent risk of HPA axis effects — particularly in pediatric populations. The FDA requires labeled safety warnings regarding this risk, and the safety context and risk boundaries for allergy covers pediatric-specific risk framing in more detail.

Common Misconceptions

Misconception 1: Antihistamines prevent all allergy symptoms.
Histamine accounts for only a subset of allergic mediators. Leukotrienes, prostaglandins, platelet-activating factor, and cytokines each contribute independent effects. Antihistamines specifically block H1 receptors and have no direct effect on leukotriene-mediated bronchoconstriction or late-phase cytokine responses.

Misconception 2: Non-sedating antihistamines have no CNS effects.
"Non-sedating" is a relative, not absolute, description. Cetirizine, while far less sedating than diphenhydramine, produces clinically measurable sedation in a subset of users. A 2001 meta-analysis cited by the FDA's advisory committee noted that cetirizine carries a higher sedation rate than loratadine in head-to-head comparisons.

Misconception 3: Decongestants treat the allergy itself.
Decongestants have no immunomodulatory properties. They address a single downstream symptom — nasal congestion — through vasoconstriction. Stopping the decongestant without addressing allergen exposure or the underlying inflammatory process will result in symptom return.

Misconception 4: Intranasal steroids work immediately.
Mucosal inflammation requires gene transcription-level intervention; this biological timeline means INCs require 1 to 2 weeks of daily use to achieve full anti-inflammatory effect. Patients who use INCs only on symptomatic days obtain substantially reduced benefit.

Misconception 5: All allergy pills work the same way.
The term "allergy medication" encompasses mechanistically unrelated compound classes. Combining an antihistamine (H1 blocker) with a leukotriene receptor antagonist such as montelukast addresses two entirely separate mediator pathways — the drugs are complementary, not redundant.

Checklist or Steps

The following is a reference checklist of the pharmacological factors involved in distinguishing among these three medication classes. This is not clinical guidance; it is a structural framework for understanding the relevant variables.

• Identify the target symptom pathway — nasal congestion, sneezing/rhinorrhea, eye itching, or urticaria each map to different receptor mechanisms
• Note generation and CNS penetrance — first-generation antihistamines carry impairment risk that second-generation formulations substantially reduce
• Check FDA OTC monograph classification — confirms which active ingredients are approved at what doses for which labeled indications (21 CFR §341 for cold/cough/allergy)
• Confirm intranasal steroid onset expectations — full effect requires consistent daily use for 1 to 2 weeks, not PRN (as-needed) dosing
• Apply the 3-day rule for topical decongestants — oxymetazoline labeling prohibits use beyond 3 consecutive days due to rebound congestion risk
• Review drug interaction categories — first-generation antihistamines potentiate CNS depressants (benzodiazepines, opioids, alcohol); this is a labeled FDA contraindication
• Check pediatric age restrictions — diphenhydramine is contraindicated in children under 2 years; INCs carry HPA axis suppression labeling for pediatric use
• Distinguish systemic from topical corticosteroid risk profiles — oral prednisone and intranasal fluticasone have fundamentally different systemic absorption characteristics

Reference Table or Matrix

Allergy Medication Class Comparison

The allergy medications overview and the antihistamines guide extend this framework into specific drug-level comparisons, including newer agents such as bilastine and rupatadine, which are approved outside the United States but under FDA review. For the full scope of allergy management from an evidence and policy standpoint, the index provides access to the complete reference architecture across all allergy topic areas.

References

• U.S. Food and Drug Administration — Drug Approvals and Databases (Drugs@FDA)
• FDA 21 CFR §341 — Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for OTC Use
• FDA 21 CFR §338 — Nighttime Sleep-Aid Drug Products for OTC Human Use
• NHLBI — Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma (2007)
• DEA Diversion Control Division — Methamphetamine Precursor Chemicals / Pseudoephedrine
• FDA Drug Approval Package — Fexofenadine HCl NDA 20-872
• [FDA — Fluticasone Propionate Nasal Spray OTC Labeling (NDA 019839)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/019839Orig1s

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)